Merck and Moderna say cancer vaccine shows promise in preventing recurrence of melanoma
Merck and Moderna’s melanoma vaccine hits key survival milestones, sending Moderna's stock soaring.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Merck and Moderna announced that their Phase 3 INTerpath‑001 trial of the mRNA‑based cancer vaccine Intismeran Autogene Plus combined with KEYTRUDA® met its primary efficacy endpoints. Coverage of the announcement varies by outlet. Business Wire, a wire‑service distributor, provided the detailed trial description, naming the INTerpath‑001 study, the vaccine formulation, and the specific RFS and DMFS endpoints in the resected melanoma cohort. CBS News highlighted the market reaction, reporting that Moderna’s share price more than doubled after the data were disclosed and describing the release as a “landmark moment” for the company. The Hill focused on the clinical implication, stating that the Moderna‑Merck mRNA vaccine prevents melanoma from returning.
The significance of the findings rests on the broader context of melanoma treatment and mRNA technology. Melanoma, an aggressive skin cancer, often recurs after surgical removal, particularly in advanced stages such as IIB through IV. KEYTRUDA® is an established checkpoint inhibitor that has been used to boost immune responses against tumors. By pairing this immunotherapy with an autogene mRNA vaccine, the collaboration seeks to generate a personalized immune attack on residual cancer cells, addressing a long‑standing need for therapies that extend disease‑free intervals. The trial’s success adds a new dimension to the expanding portfolio of mRNA‑based therapeutics that gained prominence during the COVID‑19 pandemic, illustrating a shift from infectious‑disease vaccines to oncology applications.
Future attention will turn to regulatory and commercial steps. Observers will watch for filings with health authorities that could translate the Phase 3 data into market authorization. Analysts are likely to monitor further stock movements for Moderna as investors respond to the reported efficacy and the described “landmark” status. Additional reporting on long‑term safety, subgroup outcomes, or potential expansion of the vaccine to other tumor types would also shape the trajectory of the partnership. Further statements from the companies will be needed to clarify next steps.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: unsupported claims removed (88% supported) Updated 90d ago.
Quick answers
What were the primary outcomes of the INTerpath‑001 trial?
The Phase 3 INTerpath‑001 trial met its primary endpoints of recurrence‑free survival (RFS) and distant metastasis‑free survival (DMFS) in patients with completely resected Stage IIB‑IV melanoma.
How did Moderna’s stock react to the trial results?
CBS News reported that Moderna’s share price more than doubled after the melanoma vaccine data were disclosed.
Which media outlets reported on the vaccine announcement?
Business Wire, CBS News, and The Hill each covered the story, emphasizing trial details, stock impact, and clinical implications respectively.
Coverage (9)
- Moderna shares double as cancer vaccine data rekindles investor hopes Reuters · 90d ago
- Moderna Stock Soars on Cancer Vaccine Success WSJ · 90d ago
- Daily Dose: Melanoma vaccine breakthrough, kids' eye exams, easing back-to-school nerves kare11.com · 90d ago
- A New mRNA Vaccine Could Prevent Melanoma From Returning The New York Times · 90d ago
- MSD and Moderna eye cancer vaccine market debut on Phase III melanoma score Clinical Trials Arena · 90d ago
- Moderna Stock Explodes Over 100% After Cancer Vaccine Breakthrough Yahoo Finance · 90d ago
- Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients With Completely Resected Stage IIB-IV Melano Business Wire · 90d ago
- Moderna stock more than doubles after melanoma vaccine trial shows "landmark moment" CBS News · 90d ago
- Moderna, Merck mRNA cancer vaccine prevents melanoma from returning The Hill · 90d ago
Topics
Related trends
Why the simple flu shot could be a surprise weapon against cancer
Research suggests seasonal influenza vaccines may activate immune responses against skin cancer tumors in early studies.
Moderna swings to profit as momentum for cancer vaccine builds
Moderna swings to a profit as momentum builds for its cancer vaccine, according to financial reports.
Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction
Moderna raises its 2026 outlook and swings to a profit as newer vaccines and cancer treatments gain traction.
New cancer treatment approach could help immune cells fight tumors longer
Researchers have identified a way to utilize p53 activation to enhance the potency and longevity of immune cells targeting solid tumors.
‘Zap, you’re gone.’ A Dana-Farber oncologist discusses the promising news on cancer vaccines.
Moderna and Merck's mRNA cancer vaccine reduces melanoma recurrence by 42% according to recent coverage.
First personalised cancer vaccine cuts risk of disease returning in major trial
A personalized mRNA cancer vaccine developed by Moderna and Merck cuts melanoma recurrence or death risk by 42%.